Chong Kun Dang Pharmaceutical Corp.
Symbol: 185750.KS
KSC
101200
KRWTrhová cena dnes
6.4696
Pomer P/E
-0.0542
Pomer PEG
1.29T
MRK Cap
- 0.01%
Výnos DIV
Chong Kun Dang Pharmaceutical Corp. (185750-KS) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 365065.3 | 155861.2 | 187332.6 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 145418.9 | 38444.3 | 55519.9 | |||||||||||
balance-sheet.row.net-receivables | 0 | 311468.6 | 287306.6 | 234703.7 | |||||||||||
balance-sheet.row.inventory | 0 | 261431.9 | 270081.5 | 224722.9 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 8606.1 | 365.5 | 20387.9 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 946571.9 | 713614.8 | 667147.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 319787.1 | 310697.4 | 298909.7 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 67179.1 | 5565.5 | -22146.7 | |||||||||||
balance-sheet.row.tax-assets | 0 | 14213.2 | 6208.6 | 2350.3 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2150.1 | 61843.5 | 79634.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 455856.6 | 411268 | 379552.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.account-payables | 0 | 183938.8 | 145436.3 | 129327.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 184767.4 | 124445.5 | 102091.4 | |||||||||||
balance-sheet.row.tax-payables | 0 | 43938.2 | 29026.4 | 18701.1 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 30000 | 111292.6 | 134962.3 | |||||||||||
Deferred Revenue Non Current | 0 | 1484.8 | 6438.3 | 5982 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 134996.6 | 98922.3 | 20691.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 75327.4 | 129380.9 | 160660.6 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 4996.5 | 1694.2 | 3470.5 | |||||||||||
balance-sheet.row.total-liab | 0 | 586793.3 | 503594 | 480890.4 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 31421.2 | 29970.1 | 28565.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | 218102.4 | 376370.8 | 302106.6 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 350829.8 | 276706.4 | 250156.9 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 215341.1 | -60654.3 | -14818.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 815694.5 | 622393.1 | 566010 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | -59.3 | -1104.3 | -200.3 | |||||||||||
balance-sheet.row.total-equity | 0 | 815635.2 | 621288.8 | 565809.6 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 212598 | 44009.8 | 33373.2 | |||||||||||
balance-sheet.row.total-debt | 0 | 219763.9 | 235738.1 | 237053.8 | |||||||||||
balance-sheet.row.net-debt | 0 | 117.5 | 118321.2 | 105241.1 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 212521.2 | 79977.8 | 42356.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 36942.2 | 33597.7 | 27481.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 29681.8 | -77299.3 | -71568.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -29559.7 | -51435.9 | -6926 | |||||||||||
cash-flows.row.inventory | 0 | -5980.3 | -54466.2 | -53770.6 | |||||||||||
cash-flows.row.account-payables | 0 | 38583.8 | 15824.5 | -15597.8 | |||||||||||
cash-flows.row.other-working-capital | 0 | 26638 | 12778.2 | 4725.7 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 39014.7 | 31458.4 | 14634.2 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 451.6 | 142.1 | -3448.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -192468.2 | -57181.1 | -61266.4 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 89470 | 44375.6 | 21934.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 39.8 | 347.8 | 3815.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -171312.9 | -65380.3 | -90809.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -22714.6 | -0.3 | -896.2 | |||||||||||
cash-flows.row.common-stock-issued | 0 | -3335.3 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -6025 | -1888.4 | -1935.3 | |||||||||||
cash-flows.row.dividends-paid | 0 | -11608.5 | -11238.8 | -10808.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | -16.5 | -3212.4 | 98778.7 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -43700 | -16339.8 | 85138.9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -917.6 | -410.1 | 920.1 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 102229.4 | -14395.8 | 8153.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 219646.3 | 117416.9 | 131812.7 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 117416.9 | 131812.7 | 123659.1 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 318159.9 | 67734.5 | 12903.9 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 249353.9 | 14669.8 | -38940.5 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1669404.4 | 1488344.7 | 1343559.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1014059.9 | 945705.3 | 847741.1 | |||||||||||
income-statement-row.row.gross-profit | 0 | 655344.5 | 542639.4 | 495818.3 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 408657.6 | 432733.3 | 401059.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1422717.5 | 1378438.7 | 1248800.7 | |||||||||||
income-statement-row.row.interest-income | 0 | 5789.3 | 2139 | 716.2 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 36942.2 | 34919.3 | 18187.3 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 246686.9 | 109906.1 | 94758.7 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 241403 | 97165.1 | 80593.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 27995.7 | 17187.3 | 38237.4 | |||||||||||
income-statement-row.row.net-income | 0 | 212521.2 | 80953.4 | 42720.4 |
Často kladené otázky
Čo je Chong Kun Dang Pharmaceutical Corp. (185750.KS) celkové aktíva?
Chong Kun Dang Pharmaceutical Corp. (185750.KS) celkové aktíva sú 1402428435512.000.
Aký je ročný obrat podniku?
Ročné príjmy sú N/A.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.530.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je 19599.181.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.122.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.146.
Aká je Chong Kun Dang Pharmaceutical Corp. (185750.KS) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je 212521171440.000.
Aký je celkový dlh firmy?
Celkový dlh je 219763880100.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 408657610015.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 0.000.